CytRx Corporation (NASDAQ: CYTR) and OncoMed Pharmaceuticals (NASDAQ:OMED) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, earnings, dividends, profitabiliy, valuation and risk.
Valuation & Earnings
This table compares CytRx Corporation and OncoMed Pharmaceuticals’ gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | EBITDA | Earnings Per Share | Price/Earnings Ratio | |
| CytRx Corporation | $200,000.00 | 623.42 | -$49.29 million | ($0.56) | -1.46 |
| OncoMed Pharmaceuticals | $25.02 million | 5.10 | -$97.14 million | ($2.89) | -1.17 |
CytRx Corporation has higher revenue, but lower earnings than OncoMed Pharmaceuticals. CytRx Corporation is trading at a lower price-to-earnings ratio than OncoMed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
CytRx Corporation has a beta of 2.32, suggesting that its stock price is 132% more volatile than the S&P 500. Comparatively, OncoMed Pharmaceuticals has a beta of 2.9, suggesting that its stock price is 190% more volatile than the S&P 500.
Analyst Ratings
This is a breakdown of recent recommendations and price targets for CytRx Corporation and OncoMed Pharmaceuticals, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| CytRx Corporation | 0 | 0 | 3 | 0 | 3.00 |
| OncoMed Pharmaceuticals | 0 | 6 | 2 | 0 | 2.25 |
CytRx Corporation currently has a consensus target price of $3.50, indicating a potential upside of 326.83%. OncoMed Pharmaceuticals has a consensus target price of $7.71, indicating a potential upside of 127.56%. Given CytRx Corporation’s stronger consensus rating and higher possible upside, equities analysts clearly believe CytRx Corporation is more favorable than OncoMed Pharmaceuticals.
Profitability
This table compares CytRx Corporation and OncoMed Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| CytRx Corporation | N/A | -255.43% | -88.67% |
| OncoMed Pharmaceuticals | -393.74% | N/A | -52.89% |
Institutional and Insider Ownership
11.4% of CytRx Corporation shares are held by institutional investors. Comparatively, 44.5% of OncoMed Pharmaceuticals shares are held by institutional investors. 7.5% of CytRx Corporation shares are held by insiders. Comparatively, 32.8% of OncoMed Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Summary
CytRx Corporation beats OncoMed Pharmaceuticals on 7 of the 13 factors compared between the two stocks.
CytRx Corporation Company Profile
CytRx Corporation is a biopharmaceutical research and development company specializing in oncology. The Company is focused on the clinical development of aldoxorubicin, its modified version of the chemotherapeutic agent, doxorubicin. It is engaged in Phase III trials for aldoxorubicin as a therapy for patients with soft tissue sarcoma (STS) whose tumors have progressed after treatment with chemotherapy. It is also involved in evaluating aldoxorubicin in a Phase IIb clinical trial in small cell lung cancer; a Phase II clinical trial in human immunodeficiency virus-related Kaposi’s sarcoma; a Phase II clinical trial in patients with late-stage glioblastoma (brain cancer); a Phase Ib trial in combination with ifosfamide in patients with STS, and a Phase Ib trial in combination with gemcitabine in subjects with metastatic solid tumors. It is engaged in the pre-clinical development for DK049, an anti-cancer drug conjugate that utilizes its Linker Activated Drug Release (LADR) technology.
OncoMed Pharmaceuticals Company Profile
OncoMed Pharmaceuticals, Inc. (OncoMed) is a clinical-stage biopharmaceutical company. The Company focuses on discovering and developing therapeutics that address the fundamental biology driving cancer’s growth, resistance, recurrence and metastasis. The Company’s therapeutic candidates and preclinical programs include Demcizumab (Anti-DLL4, OMP-21M18), Tarextumab (Anti-Notch2/3, OMP-59R5), Vantictumab (anti-Fzd7, OMP-18R5), Ipafricept (Fzd8-Fc, OMP-54F28), Brontictuzumab (Anti-Notch1, OMP-52M51), Navicixizumab (Anti-DLL4/VEGF Bispecific, OMP-305B83), Anti-RSPO3 (OMP-131R10), Anti-TIGIT (OMP-313M32) and GITRL-Fc trimer (OMP-336B11). Demcizumab is a humanized monoclonal antibody that inhibits Delta-like Ligand 4 (DLL4) in the Notch signaling pathway. Tarextumab is a human monoclonal antibody that binds to both the Notch2 and Notch3 receptors.
Receive News & Ratings for CytRx Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytRx Corporation and related companies with MarketBeat.com's FREE daily email newsletter.
